GeoVax Highlights Broad Cross-Protective Immunity of Multi-Antigen COVID-19 Vaccine Candidates at Keystone Symposia

Stock Information for GeoVax Labs Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About GeoVax Labs Inc.

Presenting on the Emerging Growth Conference 80, Day 1 on March 26 - Register Now
Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now
Presenting on the Emerging Growth Conference 78 Day 2 on January 16 Register Now
GeoVax Receives Notice of Allowance For Cancer Vaccine Patent
GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference
GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update
GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.